Accéder au contenu
Merck

Ephedrine- and guaifenesin-induced nephrolithiasis.

Journal of alternative and complementary medicine (New York, N.Y.) (2005-01-28)
Stephen Bennett, Nathan Hoffman, Manoj Monga
RÉSUMÉ

Ephedrine and guaifenesin are herbal supplements that have experienced increased use over the past decade. Ephedrine has been used as a stimulant and weight-loss product, guaifenesin as an expectorant and cough suppressant; both are found in combination in many antitussives and expectorants. This paper reviews the reported cases of ephedrine- and guaifenesin-induced nephrolithiasis, as well as the diagnostic techniques and treatments that have been successfully used for these stones. A systematic review of the literature pertaining to nephrolithiasis and the compounds ephedrine and guaifenesin was conducted. Ephedrine and guaifenesin use results in over 35% of urinary stones that are related to pharmaceutical metabolites, and collectively are present in 0.1% of all urinary stones. These calculi are radiolucent, requiring the use of computerized tomography (CT scan) for diagnosis. Alkalinization therapy offers an alternative to surgical intervention and may have a role in prevention of recurrence. Ephedrine and guaifenesin have been shown to cause nephrolithiasis in cases of abuse when taken individually or in combination. It is important for the clinician to be aware of the potential for these compounds to cause nephrolithiasis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Guaiacol glyceryl ether, ≥98% (GC)
USP
Guaifenesin, United States Pharmacopeia (USP) Reference Standard
Supelco
Guaifenesin, certified reference material, pharmaceutical secondary standard
Guaifenesin, European Pharmacopoeia (EP) Reference Standard